• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞癌原发肿瘤组织内的微生物群可能与静脉瘤栓的PD-L1表达相关。

Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.

作者信息

Liss Michael A, Chen Yidong, Rodriguez Ronald, Pruthi Deepak, Johnson-Pais Teresa, Wang Hanzhang, Mansour Ahmed, White James R, Kaushik Dharam

机构信息

Department of Urology, University of Texas Health San Antonio, San Antonio, TX, USA.

Greehey Children's Cancer Research Institute, University of Texas Health San Antonio, San Antonio, TX, USA.

出版信息

Adv Urol. 2020 Feb 18;2020:9068068. doi: 10.1155/2020/9068068. eCollection 2020.

DOI:10.1155/2020/9068068
PMID:32148479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7049446/
Abstract

OBJECTIVE

To perform a proof of concept microbiome evaluation and PD-L1 expression profiling in clear-cell renal cell carcinoma (cc-RCC) with associated tumor thrombus (TT).

METHODS

After IRB approval, six patients underwent radical nephrectomy (RN) with venous tumor thrombectomy (VTT). We collected fresh tissue specimens from normal adjacent, tumor, and thrombus tissues. We utilized RNA sequencing to obtain PD-L1 expression profiles and perform microbiome analysis. Statistical assessment was performed using Student's -test, chi-square, and spearman rank correlations using SPSS v25.

RESULTS

We noted the tumor thrombus to be mostly devoid of diverse microbiota. A large proportion of was detected and unknown if this is a surgical or postsurgical contaminant; however, it was noted more in the thrombus than other tissues. Microbiome diversity profiles were most abundant in the primary tumor compared to the thrombus or normal adjacent tissue. Differential expression of PD-L1 was examined in the tumor thrombus to the normal background tissue and noted three of the six subjects had a threshold above 2-fold. These three similar subjects had foreign microbiota that are typical residents of the oral microbiome.

CONCLUSION

Renal tumors have more diverse microbiomes than normal adjacent tissue. Identification of resident oral microbiome profiles in clear-cell renal cancer with tumor thrombus provides a potential biomarker for thrombus response to PD-L1 inhibition.

摘要

目的

在伴有肿瘤血栓(TT)的透明细胞肾细胞癌(cc-RCC)中进行概念验证性微生物组评估和程序性死亡受体配体1(PD-L1)表达谱分析。

方法

经机构审查委员会(IRB)批准后,6例患者接受了根治性肾切除术(RN)及静脉肿瘤血栓切除术(VTT)。我们从邻近正常组织、肿瘤组织和血栓组织中收集了新鲜组织标本。我们利用RNA测序来获得PD-L1表达谱并进行微生物组分析。使用SPSS v25软件进行统计学评估,采用学生t检验、卡方检验和斯皮尔曼等级相关性分析。

结果

我们注意到肿瘤血栓大多缺乏多样的微生物群。检测到大量的[此处原文缺失具体内容],不确定这是手术中还是术后的污染物;然而,在血栓中比在其他组织中更多见。与血栓或邻近正常组织相比,原发性肿瘤中的微生物组多样性谱最为丰富。在肿瘤血栓与正常背景组织中检测了PD-L1的差异表达,发现6名受试者中有3名的阈值高于2倍。这3名相似的受试者具有典型口腔微生物组的外来微生物群。

结论

肾肿瘤的微生物组比邻近正常组织更为多样。在伴有肿瘤血栓的透明细胞肾癌中鉴定常驻口腔微生物组谱为血栓对PD-L1抑制的反应提供了一个潜在的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/4217d38aafef/AU2020-9068068.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/1b4be400d2eb/AU2020-9068068.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/5c34ea85bfa1/AU2020-9068068.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/4217d38aafef/AU2020-9068068.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/1b4be400d2eb/AU2020-9068068.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/5c34ea85bfa1/AU2020-9068068.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2d67/7049446/4217d38aafef/AU2020-9068068.003.jpg

相似文献

1
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.肾细胞癌原发肿瘤组织内的微生物群可能与静脉瘤栓的PD-L1表达相关。
Adv Urol. 2020 Feb 18;2020:9068068. doi: 10.1155/2020/9068068. eCollection 2020.
2
Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus.伴有静脉瘤栓的肾细胞癌的免疫原性异质性
Urology. 2019 Feb;124:168-173. doi: 10.1016/j.urology.2018.09.018. Epub 2018 Oct 29.
3
Imaging predictors for assessment of inferior vena cava wall invasion in patients with renal cell carcinoma and inferior vena cava tumor thrombus: a retrospective study.肾细胞癌合并下腔静脉瘤栓患者下腔静脉壁侵犯评估的影像学预测因素:一项回顾性研究
Chin Med J (Engl). 2020 Sep 5;133(17):2078-2083. doi: 10.1097/CM9.0000000000000828.
4
Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients.原发性肾肿瘤与伴随静脉瘤栓中 PD-L1 评分的比较:治疗初治患者的回顾性、对照、单中心研究。
Adv Ther. 2021 Jun;38(6):3373-3388. doi: 10.1007/s12325-021-01737-3. Epub 2021 May 21.
5
Impact of venous tumour thrombus consistency (solid vs friable) on cancer-specific survival in patients with renal cell carcinoma.静脉肿瘤血栓质地(实性与易碎性)对肾细胞癌患者癌症特异性生存的影响。
Eur Urol. 2011 Aug;60(2):358-65. doi: 10.1016/j.eururo.2011.05.029. Epub 2011 May 24.
6
Surgical complexity and prognostic outcome of small volume renal cell carcinoma with high-level venous tumor thrombus and large volume renal cell carcinoma with low-level thrombus.小体积伴高水平静脉瘤栓肾细胞癌和大体积伴低水平瘤栓肾细胞癌的手术复杂性和预后结局。
Chin Med J (Engl). 2019 Aug 5;132(15):1780-1787. doi: 10.1097/CM9.0000000000000352.
7
Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis.肾细胞癌伴肿瘤栓子逆血流生长:手术复杂和预后不良的指标。
BMC Surg. 2021 Dec 28;21(1):443. doi: 10.1186/s12893-021-01448-0.
8
The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis.组织学对伴有静脉肿瘤栓的肾细胞癌患者临床病理结局的影响:一项匹配队列分析。
Urology. 2013 Jul;82(1):136-41. doi: 10.1016/j.urology.2013.02.034. Epub 2013 May 1.
9
The influence of venous tumor thrombus combined with bland thrombus on the surgical treatment and prognosis of renal cell carcinoma patients.静脉瘤栓合并癌栓对肾癌患者手术治疗及预后的影响。
Cancer Med. 2020 Aug;9(16):5860-5868. doi: 10.1002/cam4.3264. Epub 2020 Jul 6.
10
Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center.伴有静脉瘤栓的肾细胞癌的治疗结果:来自单一中心的大样本量和短时间跨度的经验。
BMC Cancer. 2021 Jul 2;21(1):766. doi: 10.1186/s12885-021-08508-x.

引用本文的文献

1
Advancements in understanding tumor-resident bacteria and their application in cancer therapy.肿瘤驻留细菌的认识进展及其在癌症治疗中的应用。
Mil Med Res. 2025 Jul 25;12(1):38. doi: 10.1186/s40779-025-00623-1.
2
Hot Spots in Urogenital Basic Cancer Research and Clinics.泌尿生殖系统基础癌症研究与临床热点
Cancers (Basel). 2025 Mar 31;17(7):1173. doi: 10.3390/cancers17071173.
3
The role of the urinary microbiome in genitourinary cancers.泌尿微生物群在泌尿生殖系统癌症中的作用。

本文引用的文献

1
The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling.肿瘤生态进化对肾细胞癌样本采集的影响
Cancers (Basel). 2018 Dec 4;10(12):485. doi: 10.3390/cancers10120485.
2
Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus.伴有静脉瘤栓的肾细胞癌的免疫原性异质性
Urology. 2019 Feb;124:168-173. doi: 10.1016/j.urology.2018.09.018. Epub 2018 Oct 29.
3
Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Nat Rev Urol. 2025 Mar 13. doi: 10.1038/s41585-025-01011-z.
4
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives.微生物群与泌尿系统肿瘤免疫:机制、治疗意义及未来展望
Chin J Cancer Res. 2024 Dec 30;36(6):596-615. doi: 10.21147/j.issn.1000-9604.2024.06.03.
5
Resident Microbiome of Kidney Tumors.肾肿瘤的常驻微生物群
Oncol Rev. 2024 May 21;18:1393664. doi: 10.3389/or.2024.1393664. eCollection 2024.
6
The Influence of the Microbiome on Urological Malignancies: A Systematic Review.微生物群对泌尿系统恶性肿瘤的影响:一项系统综述。
Cancers (Basel). 2023 Oct 14;15(20):4984. doi: 10.3390/cancers15204984.
7
Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma.肠道和尿路微生物群:肾细胞癌的病因和潜在治疗措施。
Front Immunol. 2023 Jun 27;14:1188520. doi: 10.3389/fimmu.2023.1188520. eCollection 2023.
8
A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC.肾癌的新治疗格局:人类微生物群与肾癌改善预后的关联
Cancers (Basel). 2023 Feb 1;15(3):935. doi: 10.3390/cancers15030935.
9
Macrophage Phenotype in Combination with Tumor Microbiome Composition Predicts RCC Patients' Survival: A Pilot Study.巨噬细胞表型与肿瘤微生物群组成相结合可预测肾癌患者的生存:一项初步研究。
Biomedicines. 2022 Jun 27;10(7):1516. doi: 10.3390/biomedicines10071516.
10
The Impact of Human Microbiotas in Hematopoietic Stem Cell and Organ Transplantation.人类微生物组在造血干细胞和器官移植中的影响。
Front Immunol. 2022 Jul 7;13:932228. doi: 10.3389/fimmu.2022.932228. eCollection 2022.
克隆异质性通过对多个患者来源的癌细胞进行体外药物测试评估影响肾癌对药物的反应性。
Int J Cancer. 2019 Mar 15;144(6):1356-1366. doi: 10.1002/ijc.31815. Epub 2018 Nov 4.
4
The urinary microbiome associated with bladder cancer.膀胱癌相关的尿微生物组。
Sci Rep. 2018 Aug 14;8(1):12157. doi: 10.1038/s41598-018-29054-w.
5
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.确定性进化轨迹影响原发性肿瘤生长:TRACERx 肾脏。
Cell. 2018 Apr 19;173(3):595-610.e11. doi: 10.1016/j.cell.2018.03.043. Epub 2018 Apr 12.
6
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.肠道微生物组对癌症、免疫和癌症免疫治疗的影响。
Cancer Cell. 2018 Apr 9;33(4):570-580. doi: 10.1016/j.ccell.2018.03.015.
7
High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia.高分辨率细菌16S rRNA基因谱荟萃分析和生物膜状态揭示常见的结直肠癌菌群。
NPJ Biofilms Microbiomes. 2017 Nov 29;3:34. doi: 10.1038/s41522-017-0040-3. eCollection 2017.
8
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.肠道微生物组影响基于 PD-1 的免疫疗法对上皮性肿瘤的疗效。
Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.
9
New treatment options for metastatic renal cell carcinoma.转移性肾细胞癌的新治疗选择
ESMO Open. 2017 May 9;2(2):e000185. doi: 10.1136/esmoopen-2017-000185. eCollection 2017.
10
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.PD-1 阻断治疗非小细胞肺癌、头颈部鳞状细胞癌和黑色素瘤后的免疫相关基因表达谱分析。
Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9.